Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/Î”M2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age